Kalaris Q2 2026 net loss $11.5 million, little changed from a year earlier; cash $93.5 million
Kalaris Therapeutics reported a second-quarter 2026 net loss of $11.5 million, nearly flat from $11.4 million a year earlier, with no revenue line in the filing. Cash, cash equivalents and marketable securities fell to $93.5 million from $118.0 million at December 31, 2025, and the company says this is expected to fund operations into the fourth quarter of 2027.
Key points
- Net loss per share was $0.48 for the quarter, versus $0.61 a year earlier, on a weighted-average share count of 23,797,306 compared with 18,701,286.
- Research and development expenses rose to $9.0 million from $8.4 million, mainly from higher clinical costs for TH103 as more sites were opened and patients enrolled.
- General and administrative expenses fell to $3.4 million from $3.8 million, mainly due to lower legal, accounting and professional fees.
- Preliminary Phase 1b/2 data for TH103 is expected in the first half of 2027, and potential Phase 3 trials remain on track to start by year-end 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.